Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
The caveat: clinical doses in those trials were generally 10 grams or more per day
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
,aspect=ignore)
The saline composition and bacteriostatic preservative system work together to support the stability of sensitive compounds during storage and in vitro experimentation
Medscape Nurses
In comparison, the unmyristoylated parent peptide 1907 displayed 0.51-fold and 0.85-fold uptake in SK-MEL-147 and WM88 cells respectively compared to TAMRA-Alkyne alone
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
